Recent Advances in Radionuclide-labeled Analogues of Exendin-4 for Insulinoma Imaging

XU Qing; YANG Min; LUO Shineng

doi:10.3971/j.issn.1000-8578.2015.04.020

Cancer Research on Prevention and Treatment > 2015 > 42(04): 407-411. > DOI: 10.3971/j.issn.1000-8578.2015.04.020

XU Qing, YANG Min, LUO Shineng. Recent Advances in Radionuclide-labeled Analogues of Exendin-4 for Insulinoma Imaging[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 407-411. DOI: 10.3971/j.issn.1000-8578.2015.04.020

Citation:

PDF (1474 KB)

Recent Advances in Radionuclide-labeled Analogues of Exendin-4 for Insulinoma Imaging

1. Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029,China; 2. Key Laboratory of Nuclear Medicine, Ministry of Health/Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China

More Information

Received Date: April 16, 2014
Revised Date: June 05, 2014

Graphical Abstract

Abstract

Abstract

Insulinoma is one of the most common pancreatic endocrine neoplasm and is difficult to be detected by typical technology. Radionuclide imaging methods such as SPECT and PET have provided a new technology for insulinoma diagnosis with advantages of non-invasive, high sensitivity and specificity. Glucagon-like peptide-1 receptor(GLP-1R) is an attractive target for imaging due to its overexpression in insulinoma. Exendin-4, the agonist of GLP-1R, could specifically bind to the receptor. This paper reviews the progress of radionuclide-labeled Exendin-4 analogs in insulinoma imaging.
- Radionuclide,
- Glucagon-like peptide-1 receptor(GLP-1R),
- Exendin-4,
- Radionuclide imaging

FullText(HTML)

References (35)

References

[1]	Okabayashi T, Shima Y, Sumiyoshi T, et al. Diagnosis and management of insulinoma[J]. World J Gastroenterol, 2013, 19(6): 82 9-37.
[2]	Ehehalt F, Saeger HD, Schmidt CM, et al. Neuroendocrine tumors of the pancreas[J]. Oncologist, 2009, 14(5): 456-67.
[3]	Chatziioannou A, Kehagias D, Mourikis D, et al. Imaging and localization of pancreatic　insulinomas[J]. Clin Imaging, 2001, 25 (4): 275-83.
[4]	Placzkowski KA, Vella A, Thompson GB, et al. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007[J]. J Clin Endocrinol Metab, 2009, 94 (4): 1069-73.
[5]	Nöldge G, Weber MA, Ritzel RA, et al. Invasive diagnostic procedures for insulinomas of the pancreas[J]. Radiologe, 2009, 49 (3): 224-32.
[6]	Guettier JM, Kam A, Chang R, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience[J]. J Clin Endocrinol Metab, 2009, 94(4): 10 74-80.
[7]	Zimmer T, Stölzel U, Bäder M, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localistation of insulinomas and gastrinomas[J]. Gut, 1996, 39(4): 56 2-8.
[8]	Reubi JC, Waster B. Concomintant expression of several peptide receptors in neuroendocrine tumours: molecure basis for in vivo multireceptor tumour targeting[J]. Eur J Nucl Med Mol Imaging, 20 03, 30(5): 781-93.
[9]	Zhang Y, Chen W. Radiolabeled glucagon-like peptide-1 analogues: a new pancreatic β-cell imaging agent[J]. Nucl Med Commun, 20 12, 33(3): 223-7.
[10]	Körner M, Stöckli M, Waser B, et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting[J]. J Nucl Med, 2007, 48(5): 736-43.
[11]	Deacon CF, Johnson AH, Holst JJ. Degradation of glucagonlike pep-tide-1 by human plasma in-vitro yields an N-terminally truncated pep-tide that is a major endogenous metabolite in vivo[J]. J Clin Endocrinol Metab, 1995, 80(3): 952-7.
[12]	Islam D, Zhang N, Wang P, et al. Epac is involved in cAMPstimulated proglucagon expression and hormone production but not hormone secretion in pancreatic alpha- and intestinal L-cell lines[J]. Am J Physiol Endocfinol Metab, 2009, 296(1): E174-81.
[13]	Bhavsar S, Mudaliar S, Cherrington A. Evolution of exenatide as a diabetes therapeutic[J]. Curr Diabetes Rev, 2013, 9(2): 161-93.
[14]	Best JH, Romley JA, Goldman DP, et al. Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens[J]. Am J Manag Care, 2012, 18 (8 Suppl): s191-202.
[15]	Underwood CR, Garibay P, Knudsen LB, et al. Crystal structure of giucagun-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-reptor[J]. J Biol Chem, 2010, 285(1): 72 3-30.
[16]	Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, all exendin-3 analogue, from heloderma suspecturn Venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas[J]. J Biol Chem, 1992, 267(11): 74 02-5.
[17]	Gotthardt M, Lalyko G, van Eerd-Vismale J, et al. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents[J]. Regul Pept, 2006, 137(3): 162-7.
[18]	Wild D, Béhé M, Wicki A, et al. [Lys40(Ahx-DTPA- 11 1In)NH2]exendin-4, a very promising ligand for glucagonlike peptide-1 (GLP-1) receptor targeting[J]. J Nucl Med, 2006, 47 (12): 2025-33.
[19]	Wicki A, Wild D, Storch D, et al. [Lys40(Ahx-DTPA-111In)NH2]- Exendin-4 is a highly efficient radiotherapeutic for glucagon-Like peptide-1 receptor targeted therapy for insulinoma[J]. Clin Cancer Res, 2007, 13(12): 3696-705．
[20]	Wild D, Mäcke H, Christ E, et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas[J]. N Engl J Med, 2008, 35 9(7): 766-8.
[21]	Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas[J]. J Clin Endocrinol Metab, 2009, 94(11): 4398-405.
[22]	Christ E, Forrer F, Wild D, et al. Glucagon-like peptide 1 receptor (GLP-1R) imaging for the preoperative localization of benign insulinomas in 30 patients[J]. Neuroendocrinology, 2012, 96 (suppl 1): 24.
[23]	Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas[J]. J Nucl Med, 2011, 52(7): 1073-8.
[24]	Wi ld D, Wi cki A, Mans i R, e t al . Exendin-4-ba s ed radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT[J]. J Nucl Med, 2010, 51(7): 1059-67.
[25]	Sowa-Staszczak A, Pach D, Miko?ajczak R, et al. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/ EDDA) NH2]-exendin-4 for the detection of insulinoma[J]. Eur J Nucl Med Mol Imaging, 2013, 40(4): 524-31.
[26]	Martin WH, Delbeke D, Patton JA, et al. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro- 2- deoxy-d-glucose[J]. Radiology, 1996, 198(1): 225-31.
[27]	Kumar R, Dhanpathi H, Basu S, et al. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging[J]. Q J Nucl Med Mol Imaging, 2008, 52(1): 50-65.
[28]	Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET)[J]. Acc Chem Res, 2009, 42(7): 832-41.
[29]	Wu Z, Todorov I, Li L, et al. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor[J]. Bioconjug Chem, 2011, 22(8): 1587-94.
[30]	Liu Z, Yan Y, Liu S, et al. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer[J]. Bioconjug Chem, 2009, 20(5): 1016-25.
[31]	Kiesewetter DO, Gao H, Ma Y, et al. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma[J]. Eur J Nucl Med Mol Imaging, 2012, 39(3): 463-73.
[32]	Kiesewetter DO, Guo N, Guo J, et al. Evaluation of an [(18)F]AlFNOTA analog of exendin-4 for imaging of GLP-1 receptor in nsulinoma[J]. Theranostics, 2012, 2(10): 999-1009.
[33]	Wu Z, Liu S, Hassink M, et al. Development and evaluation of 18F-TTCO-Cys40-Exendin-4:a PET probe for imaging transplanted islets[J]. J Nucl Med, 2013, 54(2): 244-51.
[34]	Brom M, Oyen WJ, Joosten L, et al. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET[J]. Eur J Nucl Med Mol Imaging, 2010, 37(7): 1345-55.
[35]	Vegt E, Eek A, Oyen WJ, et al. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides[J]. Eur J Nucl Med Mol Imaging, 2010, 37(2): 226-34.

Cited By

Get Citation

PDF

XML

Article views (1443) PDF downloads (694)

Turn off MathJax

Article Contents

Abstract

References

Recent Advances in Radionuclide-labeled Analogues of Exendin-4 for Insulinoma Imaging

Abstract

References

Catalog

Download Center

Links

Contact Us

Recent Advances in Radionuclide-labeled Analogues of Exendin-4 for Insulinoma Imaging

Abstract

References

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content